In:
International Journal of Cancer, Wiley, Vol. 143, No. 9 ( 2018-11), p. 2161-2167
Abstract:
What's new? Despite the lack of reliable biomarkers for risk assessment and early diagnosis, to date few metabolomics studies have been conducted to identify biomarkers for pancreatic cancer risk. In this nested case‐control study using pre‐diagnostic plasma samples, the authors identified ten metabolites associated with risk of pancreatic cancer after adjusting for multiple comparisons. Seven of these metabolites were glycerophospholipids, the majority of which were inversely associated with pancreatic cancer risk, providing novel evidence that glycerophospholipids dysregulation may be related to pancreatic cancer. The new metabolite biomarkers may be useful in identifying high‐risk individuals for screening and chemoprevention for this deadly malignancy.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8